It has been shown to reduce hepatocellular carcinoma cell proliferation by targeting SOX9 and to suppress lung adenocarcinoma cell tumorigenesis in vivo by binding to PRC1 [28,32]. This evidence concerns the gene SOX9 and lung adenocarcinoma.